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ABSTRACT 
Background Point-of-care blood gas analysis is considered a standard of care in modern air 
ambulance operations by many professional organisations for clinical assessment and 
monitoring of patients.  Instances where point-of-care blood gas analysis has identified clinically 
significant abnormalities which then led to clinical intervention are well documented and have 
been quantified previously in the air ambulance environment.  However, results obtained from 
point-of-care blood gas analysis are not always required for patient care, nor do they always 
result in any clinical action on the part of the medical crew.  Our question therefore related to the 
data for a Johannesburg based jet air ambulance service. 
Methods By means of retrospective case reviews over a one year period, we reviewed the 
overall frequency of utilisation of point-of-care blood gas analysis on patient transportations 
within a Johannesburg based jet air ambulance service.  We established how often point-of-care 
blood gas analysis yielded abnormal findings, and how frequently abnormalities detected by 
point-of-care blood gas analysis resulted in clinical interventions. 
Results Point-of-care blood gas analysis was undertaken in 266 of 334 patients 
transported (79.6%).  Abnormal findings were noted in 203 of the 338 blood gas analyses 
undertaken (60.1%).  Patient age (p=0.001) and intubation status (p=0.01) were significant 
influences on number of analyses performed, while flight time was not significant (p=0.07).  
Clinical intervention followed in 65.5% of instances where abnormalities on blood gas analysis 
were noted and in 87.6% where clinical corrective intervention was assessed as being possible 
under prevailing conditions.  Of all patients transported, some form of clinical intervention was 
undertaken following 39.3% of all blood gas analyses undertaken.  This therapeutic yield 
evidenced is equivalent to 2.54 samples analysed per corrective clinical action evidenced.  A 
costing analysis further revealed that this testing is relatively inexpensive per positive finding 
yielded and subsequent clinical actions. 
Conclusions Abnormalities detected and subsequent clinical intervention using point-of-care 
blood gas analysis in this patient population was significant with a clinical yield of 39.3%.  Since 
the costs are also not very high this modality is rightfully considered a minimum standard of care 
in air ambulance operations.  These findings also support the notion that such testing should be 
carried out routinely on all patients irrespective of clinician interpretation of indication or need.        
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1 INTRODUCTION 
 
1.1 Background 
Point-of-care testing (POCT) has its origins in ancient times when practitioners utilized tasting of 
urine for the diagnosis of diabetes mellitus (1).  Point-of-care testing in the modern sense, 
otherwise referred to as bedside or extra-laboratory testing, is achieved by utilising small bench 
top, hand held devices or test strips to measure various biochemical markers and values (2).  
Rapid provision of results at the point of care can result in better clinical decision making and 
improved patient outcomes.  This testing is however occasionally perceived in general as 
expensive relative to standard laboratory testing in terms of producing a result.  However, point-
of care testing has wider operational, economic and patient care value (2).  Moreover, it has 
been touted as a technological innovation that has the potential to improve patient care without 
in fact, increasing costs (3).  Early studies showed that Point-of-care testing reduced time taken 
to make decisions dependant on blood results and could bring about faster changes in 
treatment for which time was critical (4).   Improvements in process, such as a reduction in the 
time doctors waited for test results and the ability to make clinical decisions more quickly, did 
not seem to improve clinical outcome however (4).  Point-of-care testing has more recently been 
shown to significantly reduce the length of stay in select paediatric patients in the emergency 
department setting – in one study reducing length of stay in the emergency department on 
average by 38.5 minutes (5).  Length of stay in emergency departments has also been shown to 
be significantly decreased in chest pain patients with the use of point-of-care Troponin I testing 
by treating nurses (6).   
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Indeed, the application of these so-called point-of-care diagnostics and their application and 
utility has generated much research and debate.  In April 2006 at Arlington, Virginia a workshop 
entitled “Improving Health Care Accessibility through Point-of-Care Technologies” was held, 
jointly sponsored by the National Institutes of Health (National Institute of Biomedical Imaging 
and Bioengineering and the National Heart, Lung and Blood Institute) and the National Science 
Foundation of the United States of America (USA) (7).  The goal of this workshop which 
included both oral and poster presentations, was to bring together technology developers, 
researchers and clinicians to assess the technology developments required to advance point-of-
care testing and to identify high-priority clinical problems that could benefit from a point-of-care 
testing approach (7).  In response to recommendations from participants at this workshop, the 
Point-of-Care Technologies Research Network (POCTRN) was established (8).  The POCTRN 
was created to drive the development of appropriate point-of-care diagnostic technologies 
through collaborative efforts that simultaneously merge scientific and technological capabilities 
with clinical requirements (8). 
 
Point-of-care testing can be defined as patient specimens assayed at or near the patient with 
the assumption that results will be available immediately or within a very short timeframe to 
assist the clinician in rapid diagnosis and clinical intervention (9).  The key aspects here are 
time and proximity to patient.  In the true traditional sense, point-of-care testing refers to 
laboratory type specimen tests.  However in more recent times, with development of new 
technologies, POCT has expanded to include portable ultrasound devices and even portable CT 
scanners (10). 
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Where no laboratory facilities exist in a given environment, point-of-care testing is by default the 
only option for specimen analysis – such as in the out-of-hospital Air Ambulance environment.  
In this context, the accessibility of a specimen analysis device is the issue, rather than speed of 
analysis although this does of course also apply.  Point-of-care blood gas analysis (POC BGA) 
is considered a standard of care in modern Air Ambulance clinical assessment and monitoring 
of patients by many professional organisations including the Air Medical Physicians Association, 
Association of Air Medical Services and the Commission on Accreditation of Medical Transport 
Systems (11,12).  However, there is no clear evidence at this point that POCT improves 
outcomes in the out-of-hospital transportation environment (13).  These recommendations and 
standards, although certainly not in all aspects followed strict outcomes based evidence, have in 
fact followed the evolution of modern Air Ambulance operations.  Critical patients are routinely 
moved from distant areas to regional centres of excellence for upgrade in medical care.  
Critically ill or injured patients require intensive care level management including ventilation, 
inotropic support and fluid management.   Multiparameter monitoring is therefore required to 
properly manage the patient in a similar fashion to hospital intensive care units, including 
measurement of blood chemistry and gases using POCT technologies.   
 
1.2 Medical Transportation & Air Ambulances  
 
1.2.1 Introduction 
Modern civilian medical transport systems have evolved over many years from the original 
military systems of days gone by.  The first ever modern ambulance equivalent was probably 
used when Dominique Jean Larry, one of Napoleon’s battle surgeons used a horse-drawn 
carriage to move patients from the battlefield to a field hospital (14,15). Since then we have 
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progressed significantly and have seen the introduction of rotary wing (helicopter) air 
ambulances in the Korean and Vietnam wars as a major pre-cursor to modern organised aero-
medical systems.  In the 1960’s, military transport concepts and resources were applied to both 
trauma patients and neonates in the civilian setting (14,15).  Modern transport systems were 
then further developed into what we have today, with advanced level of care ground and air 
ambulances the world over (14).  Like transport, health care systems have been evolving over 
the years in an effort to improve care as well as optimise health care resources (14).  Tertiary 
level health care has generally become centralised.  The benefits of treating seriously ill patients 
at regional specialised centres have become recognised, and have developed into standard 
practice (14).  It was further recognised that management of the most seriously ill patients in 
tertiary Intensive Care Units (ICU’s) could actually improve their chances of survival (14-18).  A 
means to move the most seriously ill from one centre to another was no longer optional.  The 
need for rapid and safe transport of these critically ill or injured patients had become necessary.  
This need evolved and in many advanced centres resulted in the development of specialised 
transport teams for both ground and air ambulance systems (14).   
 
1.2.2 Transport vehicle options 
Three main types of transport vehicle exist for the patient today – road ambulance, fixed wing 
air ambulance, and rotor wing air ambulance.   
The road ambulance is the most commonly used form of transport for the transfer of patients 
both between hospitals, as well as from the scene of an incident.  They are generally readily 
available, and are geographically deployed to enable timeous access to different locations and 
hospitals (14).  Two fundamental principles with regards road ambulances exist.  Firstly, 
different road ambulances carry different types and level of equipment (14).  And secondly, the 
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level of training and expertise of ambulance personnel varies widely (14).  Both equipment 
levels and skill of personnel can vary from basic all the way through to advanced, with true 
mobile intensive care capability (14).    
 
The utilisation of an aero-medical resource as opposed to a ground ambulance resource is a 
much debated area.  Many different medical and governmental organisations globally have 
developed policies in this regard.  One of the more evidence based, formalised approaches is 
probably that of the American College of Emergency Physicians and the National Association of 
Emergency Medical Services (EMS) Physicians (19,20).   Air ambulance transportation is 
generally used when there is significant benefit in terms of time or medical resources to be 
gained when further distances for transport are needed. In general, air ambulances are 
equipped to a mobile intensive care level with appropriate staff.  Rotor wing (helicopter) 
transport is appropriate for shorter distances, whereas fixed wing (aeroplane) transport would 
be more feasible for longer distances (14).  Fixed wing aircraft are equipped with different types 
of engines.  Whereas piston engines are not utilised on aero-medical aircraft in general, 
turboprop and jet engines are common.  Jet and turboprop engines operate on the same 
physical principles, but jet engines produce thrust by expelling compressed gas, while turboprop 
engines produce thrust by rotating propellers attached to the engine (21).  Jet aircraft are 
capably of flying at greater speed and altitude than turboprop aircraft.   Aircraft cabins are either 
pressurised or non-pressurised.  Pressurised cabins allow for the controlling of the internal 
cabin pressure relative to that of ambient external air pressure.  In pressurised cabins, cabin 
pressure is kept at, near to or within comfortable physiological range compared to ground air 
pressure (22).     
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Rotor wing air ambulances offer direct facility to facility transportation – provided there are 
appropriate landing areas at each (14).  As a rule of thumb, they are able to travel twice as fast 
as road ambulances, and do not have to negotiate traffic on the roads.  The major 
disadvantages in this type of transportation are high noise levels, vibrations, air turbulence, 
temperature extremes and space and weight limitations (14).  The cabin of the aircraft is also 
not pressurised, and these aircraft can only fly at lower altitudes.  This combination of factors 
contributes to crew fatigue, dehydration, nausea and an inability to fully monitor or assess a 
patient clinically while in the air (14). 
 
Fixed wing air ambulances offer transportation between appropriate air fields and airports, as 
determined by both the type of aircraft and actual available air fields or airports.  Road 
transportation is then required between the hospitals and the air fields.  As a rule of thumb, fixed 
wing air ambulances can travel between five and ten times as fast as a road ambulance.  
Disadvantages include space and weight constraints, air turbulence, vibrations, and noise.  
Temperatures within the aircraft can be relatively well controlled.  Pressure changes with 
increasing altitude may offer a challenge in certain medical conditions.  Even with pressurised 
aircraft, once at cruising altitude, the cabin pressure is seldom near that of ground level 
pressure.  Cabins can be either pressurised or non-pressurised, however where the aircraft is a 
jet then the cabin is pressurised.  Adverse effects on crew are similar to that experienced in 
rotor wing aircraft, but to a lesser degree.  With the wide range of aircraft available, all these 
factors become more or less of an issue, depending on the aircraft utilised (14).   
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1.2.3 Equipment & staff 
Various groups have evaluated equipment and medications available for inter-hospital transport 
of patients on board different ambulance vehicles (both road and air) (14,23,24). On-board 
medications for ICU level transportation may include drugs such as vasoactive agents, volume 
expanders and other intravenous fluids, sedatives, analgesics, paralytics, electrolyte 
supplements, antiarrhythmics, and anticonvulsants. Equipment on board an ICU level 
ambulance generally includes all equipment necessary for advanced airway maintenance and 
ventilatory support, invasive and non invasive hemodynamic monitoring, cardiac pacing and 
defibrillation, venous access, and the capacity for arterial blood gas or electrolyte analysis 
(14,23). 
 
Although specific types or models of items of equipment will differ from place to place and 
system to system, the principle remains the same - equipment, disposables and medications 
are required to manage a patient to a level equivalent to an ICU (14).  In the context of fixed 
wing jet air ambulance operations, this is the level of care referred to in this study. 
 
Level of care not only refers to the equipment levels and specifications on board, but more 
importantly also refers to the qualifications, skills and experience of the staff in attendance.  
There are many different staffing configurations found globally.  Different air ambulance 
operators make use of specialist medical doctors (in particular anaesthetists, intensivists and 
emergency physicians), generalist medical doctors, nurses, respiratory physicians, anaesthetic 
assistants/nurses, paramedics and other emergency care practitioners.  The choice and 
combination of staffing is dependant on a number of factors, but is mainly local resource and 
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clinical requirement driven.  Standard staffing configuration may be augmented with specialised 
staff for certain cases, for example specialised neonatal transfers. 
 
1.2.4 Complications during transport 
The transport of critically ill patients is not without risk.  These risks will likely become even more 
prominent in the future, with the tendency towards centralising higher (tertiary) levels of health 
care increasing, for a number of reasons globally (14,25).  Besides the medical risks during 
transportation, there is also the risk of accidents occurring.  In a ground breaking survey in 
2008, it was found that in the USA, an air medical crew member had a death rate that exceeded 
all other hazardous professions (164 deaths/100,000 workers) (26).  This incidence rate made 
Helicopter Emergency Medical Services (HEMS) operations one of the most dangerous 
professions in the USA at that time (26).   
 
In reviews of patient transports, some specific medical problems during transport have been 
identified in addition to many general problems (14,27):  Blood pressure can be difficult to 
measure by automatic non-invasive methods or by auscultation and palpation due to vibrations, 
noise, and movements of the vehicle (ground or air ambulance); Hypotension can be 
exacerbated by movement and acceleration;  Poor lighting can make assessment of ventilatory 
movements or subtle seizures difficult;  Heating systems might not be adequate to prevent heat 
loss, especially from infants.  Stretcher positioning can be limited due to reduced flexibility of 
stretchers, which would impact on patient positioning, which could pose a problem for example 
when trying to reduce intra-cranial pressure;  Air turbulence, especially if extreme, can cause 
motion sickness in patient and crew, which can result in the crew’s inability to monitor or care for 
the patient adequately. 
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Adverse medical events and patient morbidity during transport can be further described as 
either physiologic deterioration or equipment related (14,15,28).  Physiological deterioration 
during transport has been reported as incidents of respiratory arrest or cyanosis, hypotension, 
cardiac arrest or arrhythmia, loss of consciousness, loss of brainstem reflexes, core 
temperature <34°C and hypoglycaemia (14,28).  Reported equipment related events have 
included: occluded endotracheal tube, accidental tracheal extubation, loss of intravenous 
access, pulmonary aspiration, loss of patient monitoring, malfunction of ventilator and 
exhaustion of oxygen supply (14,28).  Overall, shock and ventilatory problems appear to be the 
most common problems encountered during transport (14,28,29).  Most of these problems are 
prevented when utilising specialised transfer and retrieval teams (14,15,28,30).  Equipment and 
technical failures do occur, and whereas in the hospital setting there is in most instances the 
opportunity to acquire additional equipment from elsewhere, the transport environment is far 
more isolated from additional resources so that significant equipment failures can be 
catastrophic, unless additional backup equipment has been considered and is available (14). 
 
1.3 Equipment & devices for point-of-care testing 
Pre-hospital emergency medical transport has evolved from the simplest of transport methods 
to sophisticated, advanced life support mobile intensive care units.  Indeed, medical 
transportation now extends over land, sea and air.  As part of this development, individual items 
of medical and non-medical equipment have also evolved from minimalistic simple devices, to 
highly advanced pieces of equipment capable of providing in-hospital (or near in-hospital) 
quality of diagnostic, monitoring or therapeutic modalities and interventions. 
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Within the hospital environment, although not necessarily as dramatic, there has certainly been 
an evolution towards bringing certain diagnostic and treatment equipment items to the patient’s 
bedside as opposed to moving the patient to an area of diagnostics or treatment.  The 
development of bedside or point-of-care testing equipment has been the result. Indeed, point-of-
care diagnostics have been suggested as something that can revolutionise the quality of care in 
the ICU (10).   Point-of-care diagnostic devices include simple glucometers, dipsticks, 
ultrasound, X-ray and of course blood gas and electrolyte analysers.  Other point-of-care 
diagnostics include specific biomarkers such as B-type natriuretic peptide, rapid access D-
Dimer assays, and even novel ultra-rapid infectious disease diagnosis and antibiotic resistance 
methods (31).   
 
Insofar as POCT for blood gases and electrolytes is concerned, there are a vast number of 
products available for this purpose (32).  The i-STAT® (Abbott Laboratories, Abbott Park, 
Illinois, USA) is a portable handheld device that uses single use disposable test cartridges to 
perform a variety of diagnostic tests including cardiac markers, blood gases, chemistry and 
electrolytes, lactate, coagulation and haematology studies (33).  The cartridges are smaller than 
a business card and incorporate advanced biosensor technology and microfluidics (33).  Testing 
is performed by administering two drops of blood into the cartridge which is then closed and 
inserted into the analyser, with results available within a few minutes (33).  (See Appendix E for 
examples of diagnostic tests available utilising the i-STAT® test cartridges).  The i-STAT® has 
been shown to be equivalent to conventional laboratory blood gas analysers for blood gas 
analysis (34,35).  The i-STAT® has also been shown to be clinically adequate compared to 
conventional laboratory analysis for electrolytes and other measurements (36). 
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1.4 Point-of-care testing in hospital 
Point-of-care blood gas analysis has been validated in the hospital, Intensive Care Unit (ICU) 
and animal study settings compared to standard laboratory blood gas analysis and has been 
shown to be accurate and reliable (37,38,39).  POC testing has also been shown to be effective 
and useful in the management of critical patients in the Emergency Department (ED) (4,40).  In 
one particular study, POCT influenced treatment decisions in the ED in 14% of all patients seen 
(4). Results obtained from such POCT analyses can therefore be considered clinically 
appropriate and applicable.  The principle benefit of course is that results are obtained in a rapid 
time frame at the “point-of-care” as opposed to waiting for results to be obtained from the 
hospital central laboratory, or nearby blood gas analysers in a side ward or similar.  Studies 
have also shown significant and sustained cost savings when POCT replaces conventional 
laboratory testing in ICU’s appropriately (35). 
 
Certain devices such as glucometers have however shown significantly different values 
compared to laboratory values (41).  Recent studies have also identified certain differences 
between POC blood analysis results and central laboratory analysis.  In one series, using an 
ABL555 POC blood gas analyser, sodium values were shown to differ significantly, whereas 
potassium values were comparable to the laboratory findings (38).  The differences in sodium 
values were however not considered clinically significant, and therefore the conclusions drawn 
were that clinical decisions and actions could reliably and safely be made using these results, in 
particular related to potassium values – a finding in keeping with findings of similar earlier 
studies evaluating other POC blood gas analysers (42,43).  Discrepancies in pCO2 values using 
the i-STAT® device have also been reported and found to be related to an incompatibility 
between the sampling syringes utilised in that particular hospital at the time, and the i-STAT® 
testing system (35). 
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A key factor that needs to be considered is that with POC testing, whole blood is being used, 
whereas with central laboratory testing, serum is analysed – the biomedical technologies and 
processes involved are different, and certainly one of the reasons put forward to explain some 
of the differences identified between POCT and central laboratory results (44).  The problem is 
then really when POCT results are followed up with central laboratory results without 
consideration of potential differences or applying appropriate correction factors.  Of course 
appropriate, compatible sampling methods and equipment is also a mandatory minimum 
requirement.  Overall, POC testing in hospital is thus considered accurate and with safe clinical 
utility when used and understood correctly.  
 
1.5 Point-of-care testing out-of-hospital 
Many of the well-studied aspects of POCT relevant to hospital use can be transferred to the out-
of-hospital setting.  The key difference is of course the significantly different clinical 
environment, and there is literature available specifically regarding out-of-hospital POCT.  Point-
of-care blood gas analysis has been shown to be an accurate, rapid and reliable means of 
obtaining blood gas and electrolyte values in the out-of-hospital setting (45).  Point-of-care blood 
gas analysis has been utilised in many different out-of-hospital settings from civilian ground and 
air ambulance operations to the austere military environment.  Results obtained from these 
analyses were shown to be clinically equivalent to values obtained in the receiving hospital 
emergency department (46) or central laboratory control values (47,48).  Furthermore, instances 
where point-of-care blood gas analyses have identified clinically significant abnormalities which 
then led to clinical intervention are well documented in the air ambulance environment (45).  
13 
 
From this same study series, some abnormal blood results were assessed as potentially life 
threatening, and could not have been identified without point-of-care blood gas analysis.   
 
An early study reviewing the use of POCT using the i-STAT® portable analyser in a Helicopter 
Emergency Medical Service (HEMS) system in the USA compared the results obtained from 
POCT to those obtained using satellite or central laboratory equipment (47).  There were no 
significant differences found between the POCT results and the laboratory results, except for 
blood glucose.  The discrepancies in blood glucose were then attributed to the time delay in 
transport of the blood specimen tube to the laboratory for testing.  Clinical interventions 
following as a direct result of POCT occurred in 18.5% of the patients where POCT was 
employed. 
 
Similarly, in another early study, precision accuracy of the POCT device and comparison of 
results to laboratory values was undertaken in a ground ambulance system in the USA (46).  
The POCT device was found to be precise and reliable in the tests using control electrolytes for 
use in the pre-hospital environment of a moving ground ambulance.  Similarly, comparison to 
laboratory findings showed high correlation values for the electrolytes analysed. 
 
In a more recent small study evaluating the use of POCT in a ground ambulance system in 
Austria, emergency physicians involved in the study considered that the knowledge of blood gas 
variables were useful in 72% of patients treated and led to therapeutic intervention in 52% of all 
cases (49).  
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Six years of medical transportation cases were reviewed in another recent study (50).  Medical 
team members reported subjectively that point-of-care testing provided a moderate to 
substantial improvement in the condition of 14% of patients while there was an uncertain or no 
improvement in 86%.  Treatment decisions that were quantifiably directly linked to point-of-care 
testing results occurred in 30% of cases where point-of-care testing was employed.  The 
authors noted further that certain normal results are however still clinically significant and are 
important in patient assessment.  An example would be a normal blood gas post endotracheal 
intubation and initiation of mechanical ventilation.  Interestingly, in this particular study, results 
revealed a relatively low rate of utilisation of point-of-care testing contrary to general concern for 
a high utilisation rate due to availability and ease of use. 
 
Some potential limitations to the use of POCT in the out-of-hospital environment are 
environmental conditions.  The operating temperature of the i-STAT® is from 15°C–30°C, and 
temperature insulated or controlled storage containers/bags for both the analyser and test 
cartridges are required (13).  Test cartridges in fact require “fridge” storage conditions.  This 
potential obstacle in certain environments is easily overcome by using appropriate transport 
containers/bags, and an air-conditioned cabin in an aircraft.  If these are not achievable, then 
the use of the device will not be possible however. 
 
As useful as the technology is, results obtained from POCT however are not always required for 
patient care, nor do they always result in any clinical action on the part of the medical crew.  
When instituted in a transport environment, although remote, POCT should ideally have real-
time connectivity to receiving Emergency Departments, ICU’s as well as reference laboratories 
(13).  Preferably, any POCT structure and system should ultimately be under the control of a 
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reference laboratory in some way (13).  All factors considered, POCT is indeed a reliable and 
accurate investigative modality with established utility in the out-of-hospital setting. 
 
1.6 Quality control in point-of-care testing 
When overused or performed with poor quality, costs of POCT are unnecessarily escalated and 
risks to patients are increased (13).  The environment of the air ambulance certainly lends itself 
to both of these possibilities, with a relatively uncontrolled environment and free access to POC 
testing.  However, a good quality control system in place can minimise these risks by ensuring 
that results obtained are consistently accurate and reliable.  A good quality control system 
should link in closely with a structured operating procedure regarding POCT to control and 
regulate its use within a system.  
 
The disciplines of clinical chemistry and haematology have used well established statistical 
systems for quality control and assurance for many years (51).  POCT analysers however 
appear to present laboratory and regulatory staff with ongoing quality control dilemmas and in 
fact do not fit within any traditional laboratory quality control system – certainly partly because 
these POCT devices were never designed to be used in laboratories, nor to be used by 
laboratory staff (51).  These devices are intended for use in essentially uncontrolled (by 
laboratory standards at least) environments by clinicians.  Alternative quality control systems 
therefore become a requirement, as traditional laboratory systems are too cumbersome and 
impractical for POCT devices (1).   
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When designing a quality control system consideration needs to be given to the type of POCT 
device being used.  These fall into three broad categories, namely (i) “laboratory type,” (ii) 
“cartridge based” and (iii) “strip based” instruments (51).  It is also therefore useful to think of 
POCT as a system with an “analyser” component and a “cartridge/strip” component (51).  
Quality control processes can then be applied to each of these components, and also broadly to 
the system as a whole.   
 
An electronic quality control system is one in which the electronics of the particular device are 
tested, but without any testing of the reagents.  This system relies on a prior established fact 
that reagents are stable from the time of manufacture to the time of use, provided proper 
storage conditions were adhered to (1).  This approach was found to facilitate the performance 
and management of POCT as it eliminated the need for frequent liquid quality control (1).  This 
is the system in place for most, if not all electronic analysers with cartridge reagent components, 
as in the i-STAT® analyser.   
 
Automatic quality control is a system in which liquid quality control is automatically performed by 
the individual instrument without the need for operator intervention (1).  This could be a system 
utilised in a bench top analyser for example, but not for the average portable POCT device.  
Then in addition, some devices have automatic lock-out functions when quality control has not 
been performed, failures have been detected, or expired reagent cartridges are attempted to be 
used (1). 
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Irrespective of the type of system employed in a particular device, an established quality control 
procedure should be in place to ensure correct application of the system.  This would include 
training of staff and the institution of manufacturer recommended quality control practices and 
routines (51).  Well established and instituted training, operating procedures and quality control 
practices will combine to form a true POCT system that can be relied on by clinicians for rapid, 
accurate and reliable information.  
 
1.7 Study aims & objectives 
Point-of-care testing has indeed become well established within both the in-hospital as well as 
out-of-hospital environments.  The question addressed in this study was therefore, within a 
Johannesburg based jet air ambulance service, how often point-of-care blood gas analysis 
yielded abnormal findings.  Secondly, how frequently did point-of-care blood gas analysis result 
in clinical interventions?  Finally, the overall frequency of utilisation of point-of-care blood gas 
analysis on air ambulance missions was established. 
 
Specific objectives were: 
1. To determine the frequency that point-of-care blood gas analysis was undertaken, 
identified abnormalities and resulted in medical crew action in a specific air ambulance 
service in a one year period.  
2. To describe demographics and clinical characteristics in patients where blood gas 
analysis was undertaken. 
3. To describe the logistical characteristics of air ambulance missions where blood gas 
analysis was undertaken. 
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4. To determine the frequency of abnormalities identified in the blood gas variables that 
were pre-selected. 
5. To describe the clinical actions taken by medical flight crew following the identification of 
abnormal blood gas variables. 
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2 MATERIALS & METHODS 
 
2.1 Overview 
All medical transportation cases undertaken over the 2010 calendar year period for a 
Johannesburg based South African jet  air ambulance service were reviewed in a retrospective 
descriptive study.  Air ambulance medical evacuation and transportation missions were 
identified and extracted from all medical transportation cases, while all other non-air ambulance 
cases such as commercial medically escorted repatriations were excluded from the data 
collection.  The air ambulance medical evacuations were then reviewed, by means of a 
retrospective review of the clinical flight notes and patient records. 
 
2.2 Ethics 
Ethics approval and clearance for research was obtained from the Human Research Ethics 
Committee (Medical) of the University of the Witwatersrand (clearance certificate number 
M110108, see Appendix A and Appendix B).  Permission was obtained from the identified air 
ambulance service to undertake this review of patient records (see Appendix C). 
 
2.3 Site of study 
Johannesburg, South Africa – Air Rescue Africa, an independent private fixed wing air 
ambulance service, with dedicated air ambulance configured jet aircraft.  Air Rescue Africa is a 
fully owned subsidiary and dedicated air ambulance service provider to International SOS 
Assistance (Pty) Ltd with offices in Midrand, South Africa.    
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International SOS is a global medical and security services assistance company, supporting a 
diverse range of industries and corporations from biotechnology and financial to large oil and 
gas, mining and construction companies (52).  International SOS helps corporations manage 
the health and security risks facing their international travellers and expatriates through their 27 
alarm centres, 33 International SOS clinics, and approximately 73,000 medical, security and 
logistics providers worldwide (52).   
 
As one of these service providers to International SOS, Air Rescue Africa operates three 
dedicated jet air ambulance aircraft from their base at Lanseria International Airport.  These jet 
aircraft (two Lear Jet 35A’s and one Falcon 10) are permanently configured as air ambulances 
equipped with powered Lifeport™ stretcher systems, and modern mobile intensive care 
equipment, including on board point-of-care diagnostics capability (53). Air Rescue Africa holds 
current accreditations with the European Air Medical Institute (EURAMI) and the Commission on 
Accreditation of Medical Transport Systems (CAMTS) (54,55).  The point-of-care blood analyser 
utilized by Air Rescue Africa is the i-STAT® blood gas analyser which is standard equipment 
and available for use on every air ambulance flight.  Manufacturer specified routine 
maintenance, calibration and quality control of these devices is undertaken consistently to 
ensure correct operation on all air ambulance flights.  The staffing utilised by Air Rescue Africa 
is that of a generalist medical doctor with experience in emergency medicine, intensive care and 
transportation, paired with either an ICU/Emergency trained nurse or advanced life support 
paramedic.  The staffing is therefore to a mobile intensive care level, capable of the utilisation 
and interpretation of POC blood analysis on each and every mission undertaken.  In addition, 
medical staff is trained on the correct use of the device including calibration, testing, care of 
cartridges, and use of the device for POCT of blood samples.  
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Air Rescue Africa operates predominantly in sub-Saharan Africa, evacuating patients into 
Johannesburg South Africa from its base of aircraft operations at Lanseria International Airport.  
Lanseria International Airport is situated to the north-west of Johannesburg located within close 
proximity to Johannesburg and Pretoria hospitals to where patients are taken following the air 
ambulance flight by ground ambulance and subsequently admitted for in-patient care (see 
Figure 1). 
 
Figure 1 Location of Lanseria International Airport.   
Map showing the Location of Lanseria International Airport, in proximity to Pretoria and Johannesburg.  
(Microsoft® Encarta® 2008)  
 
2.4 Study population & sampling 
All clinical patient records of patients transported by the above air ambulance service during the 
study period of one calendar year were reviewed (see Appendix D for an example of the 
standard patient report form utilised).  Only patient records of patients transported by air 
ambulance were reviewed.  Patients transported by commercial carrier or other means besides 
air ambulance, were excluded from review.  These different mission types were identified by the 
routing and aircraft details that were recorded in the medical flight notes.  334 cases over the 
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one calendar year period of 2010 were reviewed.  Where the results of point-of-care blood gas 
analysis were not available in the flight records (illegible or omitted from the records or the 
printed results were not attached to the flight records) these patient records were recorded as 
blood gas not done.     
 
2.5 Measuring tool or instrument 
A case review sheet was designed and utilised which incorporated a checklist, yes/no answers 
and place for additional detailed information when required.  A data number was assigned per 
case reviewed and a cross-reference spreadsheet utilised to link patient flight record to data 
number, to ensure there was no duplication of individual case reviews. Once case and data 
numbers had been assigned, the cross-reference sheet was kept separate to data collection 
sheets, to maintain case anonymity. 
   
2.6 Data collection 
Manual review of clinical case notes was undertaken with appropriate recording of data on the 
case review sheet.  This review was undertaken by the researcher who is a medical doctor 
experienced in aero-medical evacuation and emergency medicine.  There was no reference on 
the case review sheet to the particular case notes reviewed, which ensured anonymity and 
patient confidentiality.  To avoid repeated review of individual case notes, an inconspicuous 
mark was made on the left lower corner of the front page of the clinical case notes.  In addition, 
a note was made on the cross-reference spreadsheet when a case review was completed.   
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Cases where point-of-care blood gas analysis was utilised were then identified.  These were 
identified by the results of blood gas analysis, or reference to the undertaking thereof being 
noted in clinical flight notes and/or the printed copies of these results attached to the clinical 
flight notes. 
 
Each set of blood gas analysis results were then reviewed to identify abnormalities.  This was 
achieved by review of the results, comparing them to a pre-defined set of standard reference 
normal values for the point-of-care blood analysis device in use (i-STAT®) and the specific test 
cartridges utilised (see Appendix E).  The selected pre-defined values that were specifically 
compared were (from i-STAT® test cartridges EG6, EG7 and CG4):  pH, partial pressure of 
oxygen (PO2) (mmHg), partial pressure of carbon dioxide (PCO2) (mmHg), standard bicarbonate 
(HCO3) (mmol/l) Base Excess (BE), oxygen saturation of haemoglobin (SO2) (%) Sodium (Na+) 
(mmol/l), Potassium (K+) (mmol/l), Haemoglobin (Hb) (g/dL) and lactate (mmol/l).   
 
Whenever an abnormal result was identified, evidence of a subsequent follow up action to 
address the blood gas abnormality by the medical flight crew was sought.  This was 
accomplished by a review of the clinical case notes, specifically looking at time of blood gas 
analysis, treatment plans, medications given, changes to ventilation parameters, changes to 
intravenous infusion regimens or any other action deemed to address the identified abnormality.   
 
Additional information gathered and recorded regarding blood sampling included time of 
sampling, location of sampling (hospital, airport tarmac, aircraft in flight), site of sampling 
(arterial venipuncture, indwelling arterial line, venous venipuncture), analyser failures and poor 
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or unclear medical records.  Further data extracted from the flight medical records included 
patient demographics age, sex, nationality (expatriate or local national), intubation status 
(intubated or not intubated), medical diagnosis category as defined by the researcher, 
destination of flight, flying times and re-fuelling stop requirements.   
 
Medical diagnosis categories were defined by the researcher and based on generic surgical 
versus medical approaches to categorisation.  The categories devised were then tailored 
according to the most common diagnosis categories identified from all the diagnoses.  This 
categorisation was done retrospectively following gathering of all the patient diagnoses, to 
enable a reasonable number of common categories to be created for this particular patient 
population, as opposed to creating a large number of categories prospectively for which there 
may or may not have been any diagnoses found to fall within any of the categories.  The 
diagnosis categories finally defined were: medical (other), medical (cardiac), medical (malaria), 
medical (neuro), surgical, trauma (other), trauma (head/spinal injury), congenital, and 
obstetrics/gynaecological.  The congenital diagnosis category refers to infants with congenital 
(almost exclusively cardiac) birth defects. 
 
2.7 Data analysis 
Microsoft® Office Excel ®2007 and Statistica™ 10.0 statistical package were utilised for data 
entry and analysis respectively.  Pearson Chi-squared and Mann-Whitney U tests for non-
parametric data were applied to appropriate data sets to determine statistical significance where 
possible.  Where statistical testing for significance was not possible, percentages and 
proportions as descriptive data were reviewed. 
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The following key variables were evaluated:  
1. The frequency that point-of-care blood gas analysis was undertaken, identified 
abnormalities, and resulted in medical crew action/clinical intervention. 
2. Number of abnormalities identified for each of the pre-selected blood gas variables. 
3. Number of occasions of clinical actions undertaken, and the numbers within each 
different category of clinical action.   
4. Number of intubated vs non-intubated patients where blood gas analysis was 
undertaken. 
5. Site of sampling (venous or arterial via stab or indwelling arterial line). 
6. Frequency of analyser failures. 
7. Duration of air ambulance missions and flying times where blood gas analysis was 
undertaken. 
8. Regional destinations (Region defined as per the United Nations (53))  
9. Physical location that blood gas analysis was undertaken (hospital, airport tarmac, or 
aircraft in flight). 
 
2.8 Study limitations & sources of bias 
Certain clinical interventions are not always possible during air ambulance missions.  Therefore, 
medical flight crew are not always able to correct certain abnormalities.  These scenarios 
include for example a significantly low Haemoglobin, where transfusion of blood products would 
normally be considered, however blood products are rarely available during flight.  In these 
cases, “no action taken” was recorded, however it does not necessarily accurately reflect the 
fact that action would have been taken if it were possible to do so.  Consideration of whether it 
was indeed possible to undertake a clinical intervention was therefore considered and included 
in the data collection and analysis.   
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Poorly documented case notes, where clear indication of either analysis or undertaking of blood 
gas was not evident.  Where this was found, the principle of “not documented not done” was 
applied.  Where notes were adequate, but the attached printed results were missing or illegible, 
and no duplication of the results written up in the case notes, the blood gas analysis results 
obtained were considered “unknown” and neither normal or abnormal assigned.  In addition, 
where incomplete clinical notes were made and treatments given were not accurately recorded 
even if they were in fact undertaken, the approach of “not recorded, not done” was taken.  
Clinical flight notes that did not reflect treatment given were counted as no action taken. 
 
Specific detailed clinical patient data for example vital signs, clinical risk or severity scores, and 
trends or responses following treatment were not recorded.  Thus assessment of outcome, 
either immediate or long term, was not possible.  Review of other accompanying case/mission 
documentation was not undertaken, thus anything not recorded in the actual clinical case notes 
could not be reviewed.  Instances of cartridge or analyser failure recorded in an incident report 
but not recorded in the clinical case notes were therefore not identified.  
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3 RESULTS 
A total of 334 air ambulance patient transport cases were reviewed.  In 266 (79.6%) of these 
patients, point-of-care blood gas analysis (POC BGA) was undertaken.   
 
3.1 Patient demographics 
A total of 334 patients were transported including 260 male and 74 female patients with a 
median age of 48 years.  Table 1 and Figure 2 show data for patient age.   Age of patient was 
found to be a significant factor related to the undertaking of POC BGA (Mann-Whitney U test Z-
adjusted=3.296, p=0.001), see Figure 3.  Patients were classified into eight diagnosis categories 
namely medical (other), medical (malaria), medical (neuro), surgical, trauma (other), trauma 
(head/spinal injury), congenital and obstetrics/gynaecological.  Table 2 and Figure 4 present 
diagnosis categories for patients evacuated numerically and graphically.  Cardiac cases (93%), 
Medical (Neuro) (89.1%) and Medical (Malaria) (88.5%) cases are listed as the categories of 
patients in whom POCT was undertaken at the highest frequencies, above the overall average 
for the entire patient population of 79.6%.   In contrast, only 20% of patients in the congenital 
diagnosis category had POCT undertaken.   
 
Further factors associated with POCT that were evaluated were patient nationality (only 
distinguishing between local national or expatriate within country of evacuation origin) and 
intubation status.  In total 79 patients were local nationals in their home country, while 255 
patients were expatriate workers or travellers.  Of the 334 patients transported, 37 (11.08%) 
were intubated while 297 (88.92%) were not intubated.  Patient nationality, sex (male or female) 
and numbers of intubated patients transported are shown in Table 3.  Where nationality and sex 
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of patient were not significant, intubation status of the patient was found to be a significant factor 
influencing the undertaking of POC BGA (Pearson Chi square, X2=5.738544, p=0.01660). 
 
Table 1 Patient Age & POCT performed 
 Number of 
Patients 
Minimum Age 
(years) 
Maximum Age 
(years) 
Median (years) 
POCT 
performed 
266 (79.6%) 0.1 86 50 
POCT not 
performed 
68 (20.4%) 0.06 90 40.5 
All Patients 334 0.06 90 48 
Table listing age data for patients in either POCT performed or not performed groups with totals for the whole patient 
population reflected in the bottom row.  Ages are in years with percentage of population in parentheses for number of 
patients in each group.  POCT = Point of Care Testing.  SD = Standard Deviation from the mean. 
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Figure 2 Distribution of Patient Ages (in years)  
Bar graph distribution of patient ages in 20 year age group categories.  Number of patients are represented on the Y-
axis, with age category (in 20 year age group categories) on the X-axis.  Expected normal distribution for ages in the 
population is line plotted over the bar graph to illustrate the non-normal distribution of ages. 
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Figure 3 Patient Age vs Blood Gas Analysis undertaken.   
Box-plot of patient ages in BGA undertaken (1) or BGA not undertaken (0) groups.  Patient age is represented on the 
Y-axis, with BGA group on the X-axis.  Age of patient was found to be significant with reference to BGA being 
undertaken.  (Mann-Whitney U test Z-adjusted=3.296, p=0.001).  BGA = Blood Gas Analysis. 
 
Table 2 Diagnosis Categories of Patients 
Diagnosis Category No. of Patients (%) BGA done BGA not done 
Medical (Other) 87 (26%) 65 (74.7%) 22 (24.3%) 
Medical (Cardiac) 57 (17.1%) 53 (93%) 4 (7%) 
Medical (Malaria) 26 (7.8%) 23 (88.5%) 3 (11.5%) 
Medical (Neuro) 55 (16.5%) 49 (89.1%) 6 (10.9%) 
Surgical 21 (6.3%) 15 (71.4%) 6 (28.6%) 
Trauma (other) 51 (15.3%) 37 (72.5%) 14 (27.5%) 
Trauma (Head/Spinal Injury) 22 (6.6%) 16 (72.7%) 6 (27.3%) 
Congenital 5 (1.5%) 1 (20%) 4 (80%) 
Obstetrics/Gynaecological 10 (3%) 7 (70%) 3 (30%) 
Total  334 266 68 
Diagnosis categories of patients listed with corresponding numbers of patients in each diagnosis category within the 
entire patient population, with percentages in parentheses.  Numbers of patients in which POCT was undertaken or 
not undertaken within each diagnosis category is then listed, with percentage within diagnosis category in 
parentheses.  BGA = Blood Gas Analysis. 
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Figure 4 Diagnosis Category of Patients Transported 
Pie-chart showing the proportions of patients in each diagnosis category within the entire population of patients 
transported.  Figures stated are percentages of the entire patient population for each individual diagnosis category. 
 
Table 3 Patient Intubation Status, Nationality & Sex with BGA performed 
Intubation 
Status 
 
BGA  Nationality  BGA  Sex  BGA  
Intubated 37 
(11.08%) 
Done 35* 
(94.59%) 
Expatriate 255 
(76.35%) 
Done 204 
(80%) 
Male 260 
(77.84%) 
Done 204 
(78.46%) 
  Not 
done 
2 (5.41%)   Not done 51 
(20%) 
  Not 
done 
56 
(21.54%) 
Not 
Intubated 
297 
(88.92%) 
Done 231 
(77.77%) 
Local 
National 
79 
(23.65%) 
Done 62 
(78.48
%) 
Female 74  
(22.16%) 
Done 62 
(83.78%) 
  Not 
done 
66 
(22.22%) 
  Not done 17 
(21.52
%) 
  Not 
done 
12 
(16.22%) 
Total 334    334    334   
Table listing patient intubation status, nationality and sex grouped by BGA analysis performed or not performed.  
Patient intubation status was found to be a significant factor influencing whether BGA was undertaken (X2=5.738544, 
p=0.0166*).  Percentages are in parentheses.  BGA = Blood Gas Analysis.  
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3.2 Flight logistics 
 
Three hundred and thirty four flights (334) were undertaken over the one year study period.  The 
median flight time was 3.3 hours with the greatest number of flights of 3-4 hours duration.  
Figure 5 and Table 4 provide flight time (with patient) data on the 334 flights performed over the 
calendar year.  Flight time with patient was not significant in influencing when POC BGA was 
undertaken (Mann-Whitney U test Z adjusted 1.789, p=0.0736). 
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Figure 5 Distribution of Flight Times (hours) 
Bar Graph of number of flights on Y-axis, with one-hour category of flight time (with patient) in hours on the X-axis. 
 
Table 4 Flying Times (with patient) 
 Number of 
Flights 
Minimum Flight 
Time (hours) 
Maximum Flight 
Time (hours) 
Mean (hours) SD (hours) 
Without Technical 
Stop 
261 0.5 4.6 2.7 0.97 
With Technical 
Stop 
73 2.5 8.0 5.9 1.31 
All Flights 334 0.5 8 3.42 1.70 
Table listing flight time data (with patient) in hours for flights grouped by technical stop requirement.  Technical stops 
would be required most frequently for aircraft refuelling purposes, and occasionally for customs entry and exit 
purposes into and out of countries of patient pick-up.  SD = Standard Deviation from the mean. 
 3.3 Regional distribution of flights
Regions from where patients were evacuated from (or in a small number of cases repatriated to) 
are shown in Table 5, with Figure 6
United Nations (53).  79% of all flights were out of Southern and Eastern Africa.
Table 5 Regional Destinations of flights
Region Number of 
Southern Africa 134 (40%)
East Africa 130 (39%)
Central Africa 30 (9%)
West Africa 33 (10%)
North Africa 0  
Islands 7 (2%) 
Total 334 
Table with number of flights conducted per regional destination.  Percentage
are in parentheses.  Regions were as defined by the United Nations, with Madagascar being included into East 
Africa, while other Indian Ocean islands were grouped into the “Islands” region.
 
 
Figure 6 United Nations Subregions of Africa
Map of Africa with subregions as defined by the United Nations in different colours
(From: http://goafrica.about.com/od/africatraveltips/ig/Maps
 
 as a visual reference to African regions as defined by the 
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3.4 Blood gas analysis results 
POC BGA was undertaken in 266 patients (see Table 1) and resulted in a total of 338 samples 
from the 334 patients transported by Air Ambulance (see Table 6 and Table 7).  These 338 
samples refer to successful sample analysis, and exclude any failed sampling attempts.  In 
certain POCT episodes, more than one test cartridge was utilised to achieve testing for all 
required parameters.  This resulted in a total of 534 cartridges being used, where 208 were 
CG4+ cartridges, 178 were EG6+ cartridges and 142 were CG7+, while there were 6 unknown 
cartridges used.  There were a total number of three reported i-Stat analyser failures identified 
from the clinical flight notes reviewed.  
 
Table 6 shows number of POCT samplings undertaken via either venous or arterial 
venipuncture, or via indwelling arterial line.  Each type of sampling techniques is then grouped 
according to location/setting in which the sampling took place.  Hospital and airport tarmac (pre-
flight) sampling accounted for 28.99% and 49.7% of all sampling respectively, while in-flight 
sampling accounted for 21.3% of all POCT.  Of the total samples, arterial sampling accounted 
for 52.3%, venous for 45.3%, while 2.4% were either arterial or venous (undetermined) (see 
Figure 7).  Proportionately, arterial sampling occurred more frequently than venous sampling in 
the hospital and in-flight settings. Arterial sampling accounted for 58.2% of samples at hospital, 
and 75% of samples in-flight.  In contrast, venous sampling accounted for 58.9% of samples in 
the airport tarmac setting.   
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Table 6 Location undertaken & sampling site of BGA 
Location Site No. of 
samples 
Hospital Venous 38 (38.8%) 
 Arterial 49 (50%) 
 Indwelling A-line 8 (8.2%) 
 Unknown 3 (3%) 
 
 
98 (28.99%) 
Airport tarmac Venous 99 (58.9%) 
 Arterial 65 (32.7%) 
 Indwelling A-line 1 (0.6%) 
 Unknown 3 (1.8%) 
 
 
168 (49.7%) 
In Flight Venous 16 (22.2%) 
 Arterial 40 (55.6%) 
 Indwelling A-line 14 (19.4%) 
 Unknown 2 (2.8%) 
 
 
72 (21.3%) 
  338 
Table listing number of POCT samples per geographical location (hospital, airport tarmac or in flight).  Site/type of 
sample taken (arterial stab, venous, or via indwelling arterial catheter) is then listed for each location.  The far right 
column lists total numbers of site/type of samples for all POCT sampling.  BGA = Blood Gas Analysis.  POCT = Point 
of Care Testing.  
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Figure 7 Site of POCT Blood Sampling  
Pie-chart depicting total percentages for all blood sampling sites of POCT for all geographical locations (hospital, 
airport tarmac or in flight).  Figures stated are percentages of all blood samples taken for each individual site of 
sampling.  POCT = Point of Care Testing. 
 
Two hundred and three (203) out of 338 samples tested (60.1%) identified an abnormality in at 
least one of the variables tested (see Table 7).  Therefore for every 1.67 samples analysed an 
abnormality was detected.  Of the 203 abnormal results identified, some form of corrective 
action followed in 133 instances – that is, an action was evidenced for every 1.53 abnormal 
POCT results (65.5%).  Overall a corrective action was taken following every 2.54 POCT 
performed.  The therapeutic yield found was therefore 39.3%.   
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Table 7 BGA performed, abnormal findings & corrective action evidenced 
BGA No. of 
Patients 
BGA 
Result 
No. of 
Findings 
Corrective 
Action  
No. of 
events 
Corrective 
Action for 
Abnormality 
 Corrective 
Action 
 
Undertaken 266 
(79.6%) 
Abnormal 203 
(60.1%) 
Taken 133 
(65.5%) 
Possible 145 
(71.4%) 
Taken 
Not taken 
127 
(87.6%)
18 
(12.4%) 
Not 
undertaken 
68 
(20.4%) 
Normal 135 
(39.9%) 
Not taken 70 
(34.5%) 
Not possible 58 
(28.6%) 
 N/A 
Total Pts 334 Total 
BGA 
338 Total AbN 
BGA 
203  203   
Table listing stepwise progression of numbers of instances from left to right columns of (1) BGA undertaken or not; 
(2) if BGA done, then whether normal or abnormal; (3) if abnormal then whether corrective action evidenced or not; 
(4) whether corrective action actually possible or not; and (5) if corrective action possible, was corrective action taken.  
BGA = Blood Gas Analysis.  AbN = Abnormal.   
 
 
Table 8 shows the number of abnormalities of specific blood gas variables identified with 
percentages in both the abnormal findings POCT group as well as the total number of POCT 
undertaken.  Of all samples analysed, pCO2 was the most frequently identified abnormality 
found in 28.1% of all samples and in 46.8% of abnormal samples.  Frequencies for pO2 and pH 
showed similar lesser values, while Na+ was found to be abnormal the least number of times in 
all samples at 2.1%. 
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Table 8 Abnormalities in Blood Gas variables identified 
Blood Gas variable No. of abnormalities 
detected  
% of  203 abnormal 
samples 
% of all 338 samples 
pH 90  44.3% 26.6% 
pO2 94  46.3% 27.8% 
pCO2 95  46.8% 28.1% 
HCO3- 68  33.5% 20.1% 
BE 78  38.4% 23.1% 
Hb 76  37.4% 22.5% 
K+ 62  30.5% 18.3% 
Na+ 7  3.4% 2.1% 
Lactate 25 12.3% 7.4% 
Table listing Blood Gas variables reviewed and number of abnormal findings for each variable.  Percentages of the 
number of abnormalities of each variable are then listed first as a percentage of the abnormal POCT identified, and 
then as a percentage of the total number of POCT undertaken.  POCT = Point of Care Testing.  
 
 
Table 9 lists the types of corrective action undertaken in response to abnormal findings.  The 
most common clinical corrective action undertaken in 25% of cases was initiation or changes to 
ventilatory support.  Administration of medications and intravenous fluid therapy were the next 
most frequent interventions at 22% and 21% respectively.  From Table 7, one can see that 
corrective action was taken on 133 occasions, while in Table 9 the total number of occasions of 
all clinical actions undertaken exceeds this number.  This is due to a combination of different 
actions being undertaken in 40% of occasions. 
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Table 9 Corrective Clinical Action undertaken 
Clinical Action No. of Occasions undertaken 
Transfusion of Blood Products 10 (5%) 
Medications administered (Bolus or Infusion) 47 (22%) 
Intravenous Fluid Administration 45 (21%) 
Oxygen Administration 32 (15%) 
Ventilatory Support or changes 54 (25%) 
General Supportive Treatment 29 (13%) 
Combination of actions 54 (40%) 
Table listing categories of clinical action and the number of occasions on which each was identified to have taken 
place following an abnormal POC BGA finding.  Total number of occasions each action was identified is represented, 
together with the percentage of that category within all actions undertaken in parentheses.  The number of occasions 
where more than one category of clinical action was undertaken following a single abnormal POCT result, was 
counted as “combination of actions” and is listed in addition to the separate actions in the bottom row. 
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4 DISCUSSION 
 
4.1 Summary of results 
Of the 334 patients transported by air ambulance, a total of 266 patients (79.6%) had POC BGA 
undertaken as part of their clinical assessment.  In these 266 patients, a total of 338 blood 
samples were taken for analysis including initial and follow up POCT.  Age and intubation status 
of patients were found to be significant determinants of whether POCT was undertaken.  Total 
flying time and sex of patient were however not significant determinants of POCT being 
undertaken.  A total of 203 abnormal blood gas results were identified (60.1%) out of these 338 
samples analysed.  Corrective clinical action for abnormal results found was noted following 133 
of the 203 abnormal blood gas results (65.5%).  Of these 203 abnormal blood gas results, it was 
established that corrective clinical action for the abnormality identified was possible in 145 
cases (71.4%).  Where corrective action was in fact possible, it was subsequently undertaken 
following an abnormal finding in 127 (87.6%) cases.  Taking all 338 POC BGA into account, a 
clinical action followed every 2.54 POC BGA undertaken, (133 actions following 338 samples).  
Therapeutic yield for POCT in this study was thus 39.3%.  The most common corrective actions 
noted were ventilatory support or changes (25%), administration of medications (22%), and 
administration of intravenous fluids (21%).  Any combination of corrective actions occurred in 
40% of cases.  These actions do appear to reflect the specific abnormalities noted and 
corrective actions clinically possible.  The most common abnormal blood gas variable noted was 
pCO2 (46.8%) followed by pO2 (46.3%) and pH (44.3%) as the next most commonly found 
abnormal blood gas variables.   
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4.2 Patient demographics 
A total of 334 patients were transported in the one calendar year period reviewed.  Of these 
patients 79 (23.65%) were local nationals in the country of pickup, while 255 (76.35%) were 
expatriates.  260 (77.84%) patients were male, while 74 (22.16%) patients were female (see 
Table 3).  This bias towards expatriates and males is very likely related directly to the client 
base and service offerings of the international medical assistance company for which the air 
ambulance service investigated is a provider (52,53).  These clients are large multinational 
mining, construction and oil and gas corporations (52) who have a business need to deploy 
technically skilled expatriate professionals and managers to take care of their international 
operations in sub-Saharan Africa.  As a rule, males are most likely preferred to go to remote 
foreign countries under potentially less than savoury conditions. These corporations who then 
follow a modern “duty-of-care” approach (52) to their employees will prefer to have seriously ill 
or injured staff reviewed and managed in medical circumstances and environment 
approximating those to which the employee is accustomed to in their home country.  Duty-of-
care is defined as a requirement that a person or organisation act towards others with 
watchfulness, attention, caution and prudence that a reasonable person in the circumstances 
would; if a person or organisation’s actions do not meet this standard of care, then the acts are 
considered negligent (57).  Johannesburg, South Africa is in many circumstances a regional 
centre of excellence for medical care in this context in sub-Saharan Africa for expatriate 
workers.  
 
Patient nationality and sex were not found to influence the undertaking of POCT.  POCT was 
undertaken in 266 (79.6%), while not undertaken in 68 (20.4%) of the 334 patients in total.  
Analysis of patient nationality showed similar figures for POCT.  204 (80%) of the 255 expatriate 
patients had POCT undertaken compared to 62 (78.48%) of the 79 local national patients.  
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Similarly, there were no differences in POCT utilisation between males and females, 78.46% 
vs.83.78% respectively.  These figures reflect that factors other than nationality and sex played 
a role in the decision to undertake POC BGA by the medical crew.  Certainly this is a finding 
that would have been expected, and if it were to have been found to be a significant factor, then 
in depth analysis around the diagnosis and clinical status of patients in these groups would have 
been required to provide further explanation. 
 
For the one calendar year reviewed, the median age of patient within the total of 334 patients 
was 48 years (see Table 1 and Figure 2).  Again, these averages probably reflect the type of 
worker employed by these multinational corporations in the sub-Saharan region in a similar 
fashion to how sex of patient was surmised to be accounted for.  It is likely that this age group 
represents a well-experienced and senior yet not necessarily the most senior or aged of a group 
of employees.  This postulation is based on the technical expertise required, but also a 
requirement for the individuals with this expertise to be willing to travel, and be in a position to 
work away from home.  Thus the average age of patient in this population studied is likely to fit 
in with these requirements. 
 
Table 1 and Figure 3 show the distribution of patient age versus POCT undertaken or not 
undertaken.   Patient age was found to be a factor influencing the undertaking of POCT.   The 
median age of 50 years for POCT undertaken does appear to mirror that of the total patient 
population of 48 years, which makes intuitive sense.  Statistical difference between the two 
groups however requires further discussion.  There is a marginally greater range of ages for 
which POCT is not undertaken (0.06 years – 90 years), compared to a relatively smaller range 
for the group where POCT is undertaken (0.1 years – 86 years).  It can be reasoned from these 
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results that the significantly younger patients had a smaller chance that POCT would be 
undertaken.  This is a feasible argument, in that clinicians are indeed far more circumspect in 
general when it comes to undertaking blood sampling in the very young or the very old.  In the 
younger patients POCT would be reserved for the more seriously ill patient where this 
investigation is considered as absolutely required.  Where this is not the case, POCT would be 
avoided in the interests of keeping the patient calm and avoiding inflicting unnecessary suffering 
on the young patient.  This concept may be responsible for only one in five patients (20%) in the 
congenital diagnosis category having POCT undertaken (see Table 2). 
 
The patient’s intubation status was found to be a statistically significant influencing factor for 
POCT to be undertaken.  In the group of patients who were not intubated, 231 (77.77%) of the 
297 patients in this group had POCT undertaken – in keeping with the proportions for the entire 
patient population of 79.6% (discussed above).  However, intubated patients had a much 
greater POCT utilisation (94.59%).  This finding is not surprising, as one would expect these 
types of investigations to be undertaken routinely in intubated patients.  This finding is also in 
keeping with further results showing common abnormalities detected, as well as corrective 
clinical actions undertaken, reflecting abnormalities and actions closely linked to respiratory and 
ventilatory function and management – discussed in sections to follow.        
 
Diagnosis categories for all patients transported are listed in Table 2.  Cardiac cases are listed 
as the category of patients in whom POCT was undertaken at the highest frequency with 93% of 
these patients having POC BGA done.  This is above the overall average for the patient 
population of 79.6%.  Other diagnosis categories with higher than population average POCT 
frequency were Medical (Malaria) (88.5%) and Medical (Neuro) (89.1%).  These figures are 
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likely to represent patients in whom POCT was deemed potentially more useful by medical staff 
due to the nature of the pathology and potential abnormalities predicted.  In contrast, only 20% 
of congenital diagnosis category patients had POCT undertaken, most likely due to their age 
and the medical staff’s intention to avoid unnecessary invasive interventions.  This is also 
reflected in the data reviewing patient age and POCT, already discussed.  Cases were not 
reviewed for categories of clinical seriousness, so this influence on decision to undertake POCT 
was not assessed. 
 
4.3 Flight logistics & regions 
Table 4 provides flight time (with patient) data on the 334 flights performed over the calendar 
year.  Figure 5 shows the distribution of flight times and visually illustrates the flight times listed 
in Table 4.  Average (mean) flight time with patient was 3.42 hours, with the shortest flight being 
30 minutes, and the longest flight 8 hours inclusive of a one hour refuelling stop.  Refuelling or 
customs clearance technical stops were required in 73 cases.  Flight time with patient was 
found not to be significant in influencing when POC BGA was undertaken (Mann-Whitney U test 
Z adjusted 1.789, p=0.0736). 
 
Since flight time as an independent factor did not influence the medical team’s decision to utilize 
POCT, the logical conclusion that follows is that this decision was based on other factors.    
However it is also clear that the non-clinical factors analysed (patient sex and flying time) have 
not influenced the utilization of POCT.  Therefore clinical or other factors (although not 
specifically reviewed in detail) must have influenced these decisions on the part of the medical 
flight crew.  It was shown that age of patient had indeed influenced whether POCT was 
undertaken.  Intubation status has already been discussed as a significant factor in the 
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utilization of POCT.  Clinical diagnosis category will be discussed in a later section.  Detailed 
clinical information was not in the scope of this study, so objective debate beyond intubation 
status and diagnosis category cannot be engaged within this paper unfortunately.  However, 
that this present study has been able to show that the non-clinical aspects of patient 
demographics and flight logistics did not influence the use of POCT is certainly both reassuring 
and significant from a clinicians perspective.   
 
Southern and Eastern Africa were the most common destinations of origin of patients flown into 
Johannesburg (see Table 5) accounting for 264 (79%) of all flights.  It is reasonable to argue 
that this dominance of patients flown out of these regions as opposed to others is related 
primarily to South Africa as a regional centre of medical excellence for referral of patients out of 
Southern and Eastern Africa.  Whereas a European destination as the nearest centre of medical 
excellence may be considered more appropriate from western, northern and northern central 
Africa.  Regional destination was not analysed separately with reference to any influence on 
POCT, as flying time was utilised and was more appropriate for this purpose. 
 
4.4 Blood gas analysis results 
POCT was undertaken in 266 patients and resulted in a total of 338 successfully analysed 
samples from the 334 patients transported (see Table 1 and Table 7).  This is equivalent to 
79.6% of all patients transported having POCT undertaken at an average of 1.27 samplings per 
patient where POCT was employed.  This number is very similar to a small study reviewing a 
doctor based ground ambulance service in Austria which showed 1.19 samplings per patient 
where POCT was undertaken (49).  This Austrian study did not however report on the total 
patient population and the percentage of patients where POCT was undertaken, which in this 
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present study was 79.6%.  Analysis of reported figures from a large six year study in a 
combined ground and air ambulance system in the USA (50) showed that only 26.8% of the 
total patient population had POCT undertaken, a significantly lower number than in the present 
study.  The investigators did report however that 66% of POCT was undertaken in patients 
graded “critical” and although specific numbers were not reported, it is reasonable to deduce 
that the lower frequency of usage of POCT could be related to lower numbers of patients in 
which POCT was deemed to be a useful part of patient assessment.   Our analysis did not 
include review of initial patient clinical data beyond clinical diagnosis category and intubation 
status.  Therefore we are unable to quantify these variables to take a view on grading the 
patients clinically in terms of severity of illness.  However, it can be surmised that the patient 
population transported in this present study had a higher percentage of “critical” cases which 
lead to a significantly higher rate of use of POCT.    
 
4.4.1 Analyser & cartridge failures   
These 338 samples above refer to successful sample analysis.  There were a total number of 
three reported i-STAT® analyser failures (0.01%), and no reported cartridge failures.  Previously 
up to 7% of testing has been reported to be compromised by failures, comprising 55% cartridge 
failures, 42% operator errors and 3% analyser failures (50).  Since our study was of a 
retrospective design, accurate analysis of errors was not possible, as the only evidence of error 
identified was if specific note was made thereof in the clinical notes, or the failed message print 
out from the i-STAT® was attached to the notes.  A separate review of cartridges purchased, 
disposed of (if expired) and utilised over the calendar year period was also not undertaken, 
which would have been a useful cross-reference for cartridge usage and errors.  Air Ambulance 
equipment failure incident reports were also not reviewed together with clinical records to 
identify failures not recorded in clinical notes.  Thus what can be reported on is a very low 
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recording in clinical notes of analyser failures, which is not likely to be due to a true low failure 
rate, but rather to the non-reporting of such in clinical notes.  This would certainly be 
appropriate, unless a failure had clinical consequence which the treating doctor wished to 
record in the patient record.  However this leads to further legal liability and ethical debate, 
which although interesting and worthy of discussion is beyond the scope of this paper.  No 
comment on actual cartridge or analyser failure rates can therefore be objectively commented 
on in the present study. 
 
4.4.2 Site and location of sampling 
Anatomical site and geographic location of blood sampling are summarised in Table 6.  Only 
21.3% of all POCT was done in flight.  The remainder (78.7%) of the POCT undertaken was 
either at the referring hospital or at the airport of patient collection.  These should be reviewed in 
the context of the operation of the air ambulance service regarding patient collection.  Patient 
collections occur either at the bedside in the referring hospital, or on the tarmac at the airport.  
All POCT at hospital or on the tarmac can therefore be considered pre-flight and as part of 
patient assessment and preparation for the flight itself.  The same is not true in the context of 
preparation for transport, as some of the POCT done on the tarmac was part of the transport 
process when the patient was collected from the bedside at the hospital.  When analysing the 
data with regards to number of “initial” patient assessment POCT versus “follow-up” POCT, 266 
(78.7%) of samples were initial assessment samples, while 72 (21.3%) of POCT was as follow 
up.  These figures are very close to other studies where 77% of testing was reported as pre-
transport (50).  The practice of comprehensive pre-transport assessment and patient 
preparation is also reflected in these high numbers of pre-transport POC BGA samples.  
Appropriate patient preparation for flight is especially important for longer duration transports.  
Here, a high proportion of POCT utilised in the pre-transport phase is related to the average 
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flight time with patient of 3.42 hours for all flights undertaken.  These transport timelines with 
patient are considered fairly long and thus thorough pre-transport assessment and preparation 
is both justified and necessary (11).  
 
Blood samples were drawn from either peripheral venous sites or arterial sites via direct 
venipuncture or indwelling arterial catheter (see Table 6).  In 2.4% of cases it was unclear as to 
the site of sampling.  Arterial blood sampling accounted for 52.4% while venous sampling for 
45.3% of POCT blood samples.  Of the total samples, arterial sampling via direct venipuncture 
comprised of 45.6%, while 6.8% was via indwelling arterial catheter.  While venous blood 
samples are adequate to assess blood electrolytes, an arterial sample is required for 
appropriate analysis and assessment of blood gases for review of oxygenation and ventilation 
status.  The slightly greater proportion of arterial vs venous samples taken could therefore 
reflect the requirements of the treating doctor in terms of information required for particular 
patient assessment.  Of interest is how the in-flight proportions are dramatically different from 
the pre-flight phase of POCT.  For the hospital and airport tarmac phases combined (i.e. pre-
flight), venous sampling accounted for 51.5%, while arterial accounted for 46.2% of samples, 
where 2.3% where from an undetermined site.  In flight however, arterial sampling and analysis 
was heavily favoured, being utilised in 75% of POCT.  Since in-flight sampling was almost 
exclusively utilised for follow-up purposes, these figures are likely to represent the greater need 
for follow-up analysis related to blood gases as opposed to electrolytes.  This is also borne out 
when reviewing the specific abnormalities detected, and the follow up clinical actions, to be 
discussed below. 
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4.4.3 Abnormalities identified & clinical actions 
Of the 338 samples from 266 patients where POCT was employed, 203 samples analysed 
identified an abnormality in at least one of the variables tested (see Table 7). Therefore, 60.1% 
of POCT samples analysed detected an abnormality.  And also, for every 1.67 samples 
analysed an abnormality was detected.  Of the 203 abnormal results identified, some form of 
corrective action followed in 133 instances, or 65.5% of the time.  This is equivalent to a clinical 
action following every 1.53 abnormal POC BGA.   
 
Further breakdown from the abnormal POCT results into categories of clinical action being 
either possible or not possible revealed interesting findings.  Corrective clinical action was 
assessed to have been possible following 145 (71.4%) of the 203 abnormal POCT results.  In 
the remaining 58 (28.6%) corrective action was noted not to have been possible.  On 21 of 
these occasions (36%) this was noted to be as a consequence of blood products not being 
available on the aircraft for that particular flight.  In the remaining cases, clinical action not being 
possible was attributed to no specific interventions available to address the abnormality.  
However the clinical notes review and data collection were not structured in a way to specifically 
address this issue, so no detailed objective comment on this aspect, besides the availability of 
blood products can be offered.   
 
Where clinical action was in fact assessed to have been possible following an abnormal POCT 
result (145 cases out of 203 abnormal), clinical action followed in 87.6% of cases.  In the 12.4% 
of cases where clinical action was possible, but not carried out, a large proportion of these were 
attributed to clinically assessed insignificant degrees of abnormality or in some cases the lack of 
clinical action was unexplained. 
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Table 8 shows the number of abnormalities of specific blood gas variables identified.  The 
highest numbers of abnormalities noted were in the blood gas variables pCO2, pO2 and pH.  
This would suggest that arterial sampling should be preferred over venous sampling as a 
standard approach, even when these are not necessarily the variables of interest initially.  
However, the marginal dominance of arterial sampling undertaken compared to venous could 
be a contributing factor to this finding.  The abnormal electrolyte findings for potassium (K+) 
reveal that K+ was found to be abnormal in 30.5% of the 203 abnormal samples, and in 18.3% 
of all samples analysed.   Abnormal K+ levels can certainly be lethal, thus identification and 
correction of this abnormality is vital.  These findings reinforce the value and necessity of 
measured K+ as part of routine patient assessment in this setting.   
 
The abnormalities noted above are also in agreement with the clinical actions undertaken where 
ventilatory support or changes were the most common clinical action noted as 25% of all 
corrective clinical actions undertaken.  Medications administered was the second most frequent 
clinical intervention at 22%.  Previously reported corrective clinical actions have included 
adjustments to mechanical ventilation being required in 30% and adjustments of FiO2 
specifically in 45% of patients based on results of POCT in transports of critically ill paediatric 
patients (45) – a figure similar although indeed greater than findings in this present study.  The 
greater numbers are certainly related to the clinical severity of illness in the paediatric transport 
review compared to patients transported in this current study, whom were from a more “general” 
patient population.  This of course is speculative and intuitive, as the clinical severity of cases 
was not reviewed in the present study. 
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Table 9 lists the further types of corrective action undertaken in response to abnormal findings.  
It is evident from the preceding comments and inspection and comparison of Table 8 and Table 
9 that findings and actions cover multiple different simultaneous abnormalities and consequent 
clinical actions.  This eye-ball review is then confirmed by 40% of occasions of clinical actions 
having required a combination of different types of action.   
 
4.4.4 Therapeutic yield 
Taking all 338 POC BGA into account, a clinical action followed every 2.54 POC BGA 
undertaken, (133 actions following 338 samples).  As a percentage, this equates to an action 
undertaken following blood gas analysis in 39.3% of POCT events.  Therapeutic yield for POCT 
in this study was thus 39.3%.  Other studies show therapeutic yields of 30% and 52% (49,50) 
which appears therefore to place our findings on a similar level to previous findings.  Subjective 
questionnaire based findings have previously reported treating doctors to have found the results 
of POCT to be useful in 72% of cases (49).  In another descriptive study, interviewing the 
attending doctor following the inter hospital transport of critically ill children, it was shown that 
results of POCT influenced treatment in 76.5% of all samples (45).  This number is significantly 
higher than our findings, and it is most likely related to the paediatric patients in this study being 
critically ill in almost all instances. 
 
Although our study did not assess the opinions of treating doctors specifically, we did show that 
79.6% of patients had POCT revealing abnormalities in 60.1% of these cases.  It is not only 
abnormal results that are useful, but indeed confirmation of normal findings that are also useful 
to the attending clinician.  It is therefore reasonable to argue that POCT was useful in this 
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present study in a range between 47.8% (60.1% of 79.6%) up to 79.6% of all patients evaluated 
and transported. 
 
In conclusion, these findings show frequent usage of POCT, followed by frequent detection of 
abnormalities and resultant clinical actions, with an overall therapeutic yield of 39.3%.  Thus it 
would certainly be reasonable to suggest that within this air ambulance service, that POCT be 
instituted as mandatory for all patients.  Arterial sampling as a standard technique rather than 
venous sampling could also well be a further consideration.  Further evaluation of patient 
outcomes would be of significant value in determining the true utility of POCT in this setting. 
 
4.5 Costing analysis 
A total of 534 i-STAT® test cartridges were used, which included 208 CG4+ cartridges, 178 
EC6+ cartridges and 142 CG7+ cartridges. There were 6 unknown cartridges used.  As some 
variables included in one cartridge are not included in others, it is sometimes necessary to 
utilise two cartridges per POCT occasion.  Thus across all POCT events the average number 
used per POCT was 1.58 cartridges.   The costs of all the aforementioned cartridges to the air 
ambulance service are equivalent at ZAR83.67 per cartridge.  Therefore the cost of cartridges 
per POCT undertaken was ZAR132.20.  There were a total of 203 abnormal POC BGA sample 
results identified from all samples analysed, translating to a cost therefore of ZAR220.10 per 
abnormal sample result.  Similarly, from the 133 corrective clinical actions noted following 
POCT, the cost per clinical action (or cost of therapeutic yield) was ZAR335.90.  In the context 
of the costs involved in other diagnostic investigations, this is certainly not expensive.   
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It must be noted however that the above are only the costs of the i-STAT® test cartridges.  And 
further, that the number of discarded failed cartridges was not possible to establish in this study 
design, so there were certainly a small number of additional cartridges that should be 
considered in this analysis.  Additional costs would also include the heparinised syringes, 
hypodermic needles, alcohol swabs, gauze and any other disposable items required to 
undertake the sampling.  These costs would be relatively small compared to the cost of the test 
cartridges.  The capital expense of the i-STAT® analyser (approximately ZAR65,000.00) should 
also be considered.  However, this particular expense could be considered as part of the 
general capital operating costs, and for the purposes of understanding individual POCT 
occasions, be excluded.  Finally, costs of i-STAT® test cartridges and other disposable items 
utilised for training purposes should also be included in an analysis of true costs of POCT within 
any particular system. 
 
4.6 Limitations 
In addition to issues already raised in preceding sections, some general comments are worth 
noting at this point.  Since this was a retrospective review of clinical case notes, certain aspects 
related to POCT could not be accurately evaluated.  Failure rates for analyser and cartridges 
are very likely to be much higher than the three identified reported failures.  Failure rate is an 
important aspect in POCT that could not be assessed in this study.  A greater positive finding in 
terms of numbers of abnormalities detected could well have been elicited if all variables 
measured were assessed.  By design, a certain subset of blood gas variables was pre-chosen, 
and therefore other variables that may have been measured were not evaluated.  A prospective 
design taking these issues into account would be a solution.   
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Review and analysis of clinical parameters utilising scoring systems and the like would have 
been useful in providing analysis and commentary on the influence of patient clinical status on 
attending medical personnel’s use of POCT.  It is quite likely that a correlation between clinical 
severity and use of POCT would be found.   
 
No means to distinguish between clinical actions undertaken as a direct result of information 
obtained from POCT or those undertaken as a result of other clinical assessment or 
combination of assessment variables and methods was possible.  For the purposes of this 
study, the design was such that it assumed actions intended to correct an abnormality were 
undertaken as a consequence of being provided with that information from POCT, and not by 
any other means such as clinical examination or clinician intuition and analysis.  Thus, the 
figures related to clinical actions and final therapeutic yield are certainly not conservative, and 
could be lower in practice if these factors had been analysed.  A prospective study design 
including a questionnaire based process to evaluate the clinicians decision process would be a 
good option to evaluate and understand this particular aspect. 
 
Finally, no review of clinical investigation and intervention would be complete without a review of 
clinical outcomes.  Further study and review of clinical progression and outcome within the 
system studied would be of great value in this regard. 
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5 CONCLUSIONS 
5.1 Summary 
Point-of-care testing when used appropriately has the potential to improve patient outcomes.  
However, when overused or performed with poor quality, costs are unnecessarily escalated and 
risks to patients are increased (13).  The environment of the air ambulance certainly lends itself 
to both of these possibilities, with a relatively uncontrolled environment and free access to POC 
testing.  However, with a good quality control and training system in place, together with prudent 
decision making on the part of the medical team, these risks can be minimised.  Certainly, 
POCT is considered a standard of care in modern Air Ambulance clinical assessment and 
monitoring of patients by many professional organisations (11).   
 
Point-of-care testing carried out in 79.6% of the population in this study showed 60.1% of the 
POCT samples to have at least one abnormal value.  Clinical intervention followed in 65.5% of 
instances where abnormalities on blood gas analysis were noted and in 87.6% where clinical 
corrective intervention was assessed as actually being possible.  Patient age and intubation 
status were significant influences on number of analyses performed, while flight time was not 
significant.  Overall the therapeutic yield for all blood gas analyses undertaken and follow up 
clinical action evidenced was 39.3%.  Thus these results are similar to findings in other previous 
studies on POCT in different transport systems.  The costs of i-STAT® sample cartridges 
utilised were calculated at ZAR132.20 per POCT undertaken, ZAR 220.10 per abnormality 
detected, and ZAR 335.90 per clinical action executed. 
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Results show that POCT yielded a high percentage of abnormal results within the patient 
population and resulted in a high number of clinical actions undertaken as a result. Since the 
costs have been shown not to be very high, this modality is rightfully considered a minimum 
standard of care in Air Ambulance operations.  These findings support the notion that point-of-
care blood gas analysis and testing should be carried out routinely on all patients, irrespective of 
the attending clinician’s interpretation of the clinical indication or need thereof.  Further, that 
arterial sampling in preference to venous sampling can also be recommended. 
 
5.2 Recommendations 
A careful review of available test cartridges to identify (if possible) a single cartridge with 
appropriate combinations of the most common abnormal variables and essentially required 
variables would not only potentially reduce costs, but also standardise the usage of POCT.  
Further study, specifically in the sub-Saharan African setting, could include the undertaking of a 
prospective study evaluating the clinical status of patients undergoing POCT, including a 
questionnaire administered to attending air medical crew to evaluate the decision making 
process and perceived utility of POCT.  A follow up study designed around using POCT in all 
patients transported with similar objectives would then add further insights.  Of significant value 
to include in these studies would be the evaluation of the change in clinical status of patients 
following POCT and clinical interventions following testing with the objective to quantify the 
clinical benefits and outcomes following POCT.  The evaluation of all parameters tested, instead 
of the review of a pre-defined set of variables should also reveal additional abnormalities 
identified using POCT. 
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Together with further studies and evidence, the findings from this present study can certainly 
form part of an evidence base, if not potentially independently, to promote the use of POCT in 
all patients transported via air ambulance in the sub-Saharan African setting, as standard 
practice guidelines. 
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